Skip to main content
. 2023 Jan 10;8(1):e165207. doi: 10.1172/jci.insight.165207

Figure 1. C-10 is a TYRO3 agonist.

Figure 1

(A) Cultured human podocytes were treated with control vehicle (C) or TYRO3 agonists (compounds 1–12) for 30 minutes. Cell lysates were probed for phosphorylated or total TYRO3 (p-TYRO3 or t-TYRO3). GAPDH was used as a loading control. (B) Cultured human podocytes were stimulated with compound 10 (C-10) for 30 minutes at different doses as indicated, and cell lysates were probed for p-TYRO3 or t-TYRO3 and for p-AKT or t-AKT. GAPDH was used as a loading control. (C) Cultured podocytes were treated with vehicle control (C), 10 μM TNF-α alone (T), or TNF-α with TYRO3 agonists (compounds 1–12) for 2 hours. Real-time PCR analysis was performed for expression of NF-κB target genes, IL6 and CCL2 (n = 3). *P < 0.05, **P < 0.01 compared with TNF-α–treated cells by 1-way ANOVA with Bonferroni’s correction.